Table 4.
Baseline characteristics among Huntsman patients with cancer in the prospective validation study.
| Characteristics | Categories | Hold out cohort N = 633 |
Deliverable cohort N = 603 |
||||
|---|---|---|---|---|---|---|---|
| Overall | High risk n = 61 |
Low risk n = 572 |
Overall | High risk n = 44 |
Low risk n = 559 |
||
| Age (years) | Median | 65 | 63 | 65 | 65 | 64 | 65 |
| Mean (range) |
63 (20–95) |
62 (29–95) |
63 (20–95) |
63 (20–93) |
62 (28–88) |
63 (20–93) |
|
| Gender, n (%) | Male | 300 (47) | 27 (44) | 273 (48) | 278 (46) | 24 (55) | 254 (45) |
| Female | 333 (53) | 34 (56) | 299 (52) | 325 (54) | 20 (45) | 305 (55) | |
| Ethnicity, n (%) | Hispanic | 51 (8) | 8 (13) | 43 (8) | 41 (7) | 5 (11) | 36 (6) |
| Non-Hispanic | 582 (92) | 53 (87) | 529 (92) | 562 (93) | 39 (89) | 523 (94) | |
| Race, n (%) | White | 529 (84) | 49 (80) | 480 (84) | 512 (85) | 33 (75) | 479 (86) |
| Black | 10 (2) | 1 (2) | 9 (2) | 10 (2) | 3 (7) | 7 (1) | |
| Asian | 15 (2) | 3 (5) | 12 (2) | 16 (3) | 2 (5) | 14 (3) | |
| Other | 66 (10) | 8 (13) | 58 (10) | 52 (9) | 6 (14) | 46 (8) | |
| Unknown | 13 (2) | 0 (0) | 13 (2) | 13 (2) | 0 (0) | 13 (2) | |
| Medicaid, n (%) | Yes | 76 (12) | 28 (46) | 48 (8) | 63 (10) | 16 (36) | 47 (8) |
| No | 557 (88) | 33 (54) | 524 (92) | 540 (90) | 28 (64) | 512 (92) | |
| H@H enrollment at index encounter, n (%) | Yes | 20 (3) | 9 (15) | 11 (2) | 26 (4) | 9 (20) | 17 (3) |
| No | 613 (97) | 52 (85) | 561 (98) | 577 (96) | 35 (80) | 542 (97) | |
| Number of cancer diagnosis, n (%) | 1 | 309 (49) | 28 (46) | 281 (49) | 295 (49) | 17 (39) | 278 (50) |
| 2 | 175 (28) | 13 (21) | 162 (28) | 150 (25) | 14 (32) | 136 (24) | |
| 3 | 80 (13) | 7 (11) | 73 (13) | 75 (12) | 6 (14) | 69 (12) | |
| 4 | 31 (5) | 6 (10) | 25 (4) | 40 (7) | 4 (9) | 36 (6) | |
| ≥5 | 38 (6) | 7 (11) | 31 (5) | 43 (7) | 3 (7) | 40 (7) | |
| Cancer Sitesa, n (%) | Breast | 129 (20) | 3 (5) | 126 (22) | 129 (21) | 2 (5) | 127 (23) |
| Unspecified primary malignant neoplasms | 123 (19) | 18 (30) | 105 (18) | 152 (25) | 14 (32) | 138 (25) | |
| Non-melanoma skin neoplasms | 111 (18) | 9 (15) | 102 (18) | 117 (19) | 6 (14) | 111 (20) | |
| Prostate | 95 (15) | 8 (13) | 87 (15) | 83 (14) | 6 (14) | 77 (14) | |
| Lung | 63 (10) | 11 (18) | 52 (9) | 66 (11) | 5 (11) | 61 (11) | |
| Multiple myeloma | 56 (9) | 2 (3) | 54 (9) | 70 (12) | 8 (18) | 62 (11) | |
| Non-Hodgkin’s lymphoma | 54 (9) | 6 (10) | 48 (8) | 65 (11) | 5 (11) | 60 (11) | |
| Leukemia | 53 (9) | 7 (11) | 46 (8) | 57 (9) | 3 (7) | 54 (10) | |
| Colon | 46 (7) | 11 (18) | 35 (6) | 31 (5) | 5 (11) | 26 (5) | |
| Melanoma of skin | 42 (7) | 5 (8) | 37 (6) | 45 (7) | 3 (7) | 42 (8) | |
| Bone/connective tissue | 40 (6) | 5 (8) | 35 (6) | 43 (7) | 4 (9) | 39 (7) | |
| Kidney/renal pelvis | 35 (6) | 6 (10) | 29 (5) | 26 (4) | 1 (2) | 25 (4) | |
| Rectum | 33 (5) | 9 (15) | 24 (4) | 21 (3) | 2 (5) | 19 (3) | |
| Ovary | 31 (5) | 3 (5) | 28 (5) | 28 (5) | 4 (9) | 24 (4) | |
| Uterus | 30 (5) | 2 (3) | 28 (5) | 22 (4) | 3 (7) | 19 (3) | |
| Brain | 29 (5) | 4 (7) | 25 (4) | 26 (4) | 3 (7) | 23 (4) | |
| Head and neck | 27 (4) | 4 (7) | 23 (4) | 34 (6) | 4 (9) | 30 (5) | |
aOnly cancer sites with >5% prevalence at baseline are listed in the table.
H@H Huntsman at Home Program.